The RNA-dependent RNA polymerase (RdRp) is a key enzyme which regulates the viral
replication of SARS-CoV-2. Remdesivir (RDV) is clinically used drug which targets RdRp …

SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) protein is the target for the antiviral
drug Remdesivir (RDV). With RDV clinical trials on COVID-19 patients showing a reduced …

RNA-dependent RNA polymerase (RdRp), also called nsp12, is considered a promising but
challenging drug target for inhibiting replication and hence, the growth of various RNA …

Development of new drugs is a time-taking and expensive process. Comprehensive efforts
are being made globally toward the search of therapeutics against SARS-CoV-2. Several …

The outbreak of a new coronavirus SARS-CoV-2 (severe acute respiratory syndrome–
coronavirus 2) has caused a global COVID-19 (coronavirus disease 2019) pandemic …

Antiviral drug therapy against SARS-CoV-2 is not yet established and posing a serious
global health issue. Remdesivir is the first antiviral compound approved by the US FDA for …

The efforts towards developing a potential drug against the current global pandemic, COVID-
19, have increased in the past few months. Drug development strategies to target the RNA …

Remdesivir was the first antiviral drug that received emergency use authorization from the
United States Food and Drug Administration and is now formally approved to treat COVID …

Starting from late 2019, the coronavirus disease 2019 (COVID-19) has emerged as a once-
in-a-century pandemic with deadly consequences, which urgently calls for new treatments …

COVID-19, a disease caused by a new strain of coronavirus (SARS-CoV-2) originating from
Wuhan, China, has now spread around the world, triggering a global pandemic, leaving the …